Abstract | AIMS: A mechanism for co-operation between the serotonin (5-hydroxytryptamine, 5-HT) transporter and 5-HT1B receptor in mediating pulmonary artery vasoconstriction and proliferation of pulmonary artery smooth muscle cells has been demonstrated in vitro. Here we determine, for the first time, the in vivo effects of a combined 5-HT1B receptor/ serotonin transporter antagonist ( LY393558) with respect to the development of pulmonary arterial hypertension (PAH) and its in vitro effects in human pulmonary artery smooth muscle cells (hPASMCs) derived from idiopathic PAH (IPAH) patients. METHODS AND RESULTS: CONCLUSION:
|
Authors | Ian Morecroft, Louisa Pang, Marta Baranowska, Margaret Nilsen, Lynn Loughlin, Yvonne Dempsie, Caroline Millet, Margaret R MacLean |
Journal | Cardiovascular research
(Cardiovasc Res)
Vol. 85
Issue 3
Pg. 593-603
(Feb 01 2010)
ISSN: 1755-3245 [Electronic] England |
PMID | 19736308
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cyclic S-Oxides
- LY 393558
- Serotonin 5-HT1 Receptor Antagonists
- Serotonin Uptake Inhibitors
- Thiadiazines
- Citalopram
|
Topics |
- Animals
- Cell Proliferation
(drug effects)
- Citalopram
(administration & dosage)
- Cyclic S-Oxides
(administration & dosage)
- Female
- Hypertension, Pulmonary
(drug therapy, pathology)
- Mice
- Mice, Inbred C57BL
- Mice, Inbred CBA
- Serotonin 5-HT1 Receptor Antagonists
- Selective Serotonin Reuptake Inhibitors
(administration & dosage)
- Thiadiazines
(administration & dosage)
- Vasoconstriction
(drug effects)
|